Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.86M | $6.39M | $146K | — | $0.00 | $398K | $2.92M | $5.00K | $10.0K | $5.00K |
| Revenue growth | — | -6.9% | -97.7% | — | — | — | 634.2% | -99.8% | 100.0% | -50.0% |
| Operating income | -$165M | -$53.5M | -$53.9M | -$57.9M | -$80.4M | -$77.5M | -$35.1M | -$34.3M | -$4.81M | -$4.22M |
| Operating margin | -2409.4% | -837.3% | -36921.9% | — | — | -19484.7% | -1201.4% | -685340.0% | -48120.0% | -84500.0% |
| Net income | -$165M | -$54.3M | -$53.1M | -$118M | -$80.0M | -$78.8M | -$37.7M | -$4.68M | -$4.68M | -$4.18M |
| Net margin | -2409.2% | -850.3% | -36381.5% | — | — | -19786.7% | -1291.2% | -93580.0% | -46790.0% | -83520.0% |
| EPS (diluted) | -$1.32 | -$0.53 | $0.96 | -$0.70 | -$0.38 | -$0.37 | -$2.61 | -$21.97 | -$2.92 | -$2.20 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$58.3M | -$54.7M | -$49.5M | -$40.9M | -$57.0M | -$61.5M | -$29.2M | -$30.1M | -$4.97M | -$2.87M |
| Capital expenditures | $551K | $737K | $459K | $284K | $9.78M | $3.32M | $216K | $197K | $0.00 | $98.0K |
| Free cash flow | -$58.9M | -$55.4M | -$49.9M | -$41.1M | -$66.8M | -$64.8M | -$29.4M | -$30.3M | -$4.97M | -$2.97M |
| Share buybacks | $2.00K | $0.00 | $1.62M | $653K | — | $0.00 | $45.0K | $0.00 | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $81.1M | $70.9M | $61.7M | $79.7M | $115M | $76.1M | $39.1M | $6.06M | $1.09M | $1.39M |
| Total assets | $106M | $106M | $95.1M | $109M | $146M | $94.9M | $64.9M | $8.26M | $2.75M | $2.97M |
| Total liabilities | $58.3M | $58.4M | $9.49M | $14.1M | $22.4M | $36.8M | $26.4M | $1.96M | $692K | $813K |
| Long-term debt | — | — | — | — | $0.00 | $16.3M | $0.00 | $0.00 | $0.00 | — |
| Shareholders' equity | -$77.3M | -$96.8M | $85.6M | $95.0M | $124M | $58.1M | $38.6M | $6.31M | $2.06M | $2.15M |
| Retained earnings | -$658M | -$712M | -$566M | -$684M | -$764M | -$843M | -$881M | -$916M | -$920M | -$925M |
| Shares (wtd avg diluted) | 130M | 137M | 144M | 168M | 210M | 214M | 14.5M | 1.60M | 1.60M | 1.95M |
Every figure is extracted from Alaunos Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.